Biogen has announced exciting new data revealing significant motor milestone achievements in children with Spinal Muscular Atrophy (SMA) who have received previous gene therapy treatment. This breakthrough was unveiled during their latest presentation, showcasing the efficacy of Salanersen, a treatment option aimed at enhancing motor function in young SMA patients. The findings indicate that children displayed improved motor skills, which could signal a turning point in SMA treatment strategies. Biogen’s innovative research emphasizes the potential of Salanersen to complement existing gene therapies, offering renewed hope to families affected by this rare genetic disorder. As Biogen continues to lead in neurological research, their commitment to developing advanced therapies highlights the progressive landscape of SMA treatments, creating new opportunities for young patients worldwide. These developments underscore the importance of ongoing research in the quest to improve life quality for patients with SMA.
BiogenNew data shows increase in five-year cancer survival rates
April 6, 2026
In recent findings shared by Good Morning America, new data highlights a promising trend in cancer survival, revealing that more individuals are now living at